Skip to main content

Detection of truncated HER2 forms in formalin-fixed, paraffin-embedded breast cancer tissue captures heterogeneity and is not affected by HER2-targeted therapy.

Krüger JM, Thomas M, Korn R, Dietmann G, Rutz C, Brockhoff G, Specht K, Hasmann M, Feuerhake F

Publication: Am J Pathol (2013) • Vol 183 • Page 336-43PMID: 23727348View on PubMed

Purpose

This paper investigated effects associated with specimen acquisition method (surgical versus core needle biopsy), specimen heterogeneity, analysis method (automated versus manual visualization), and targeted therapies using antibodies against human epidermal growth factor receptor 2 (HER2) on the pattern and levels of full length and total HER2 by immunohistochemistry (IHC) and Western blot analysis.

Conclusion

While generally IHC staining of core needle biopsy (CNB) specimens was comparable to that observed among surgical specimens, the staining of CNB specimens was more intense and consistent.

HER2 IHC staining showed heterogeneity in the ratio of full-length (antibody against extracellular domain, ECD) to total (antibody against intracellular domain, ICD) HER2 within regions of the tumor, specifically between the tumor center and periphery. The coefficient of variance between images could be minimized by analysis of at least 250 viable and intact cells or 3-8 fields of view at a magnification of 20X. Results of automated and manual analysis of HER2 IHC staining were in agreement for 91 of the 138 cases (66%), with more cases identified with a loss of the ECD of HER2 by manual analysis than automated. The HER2 IHC assay was not affected by targeted therapies using antibodies against HER2, and the ratio of full length HER2 to total HER2 was negatively correlated with truncated HER2 levels as detected by Western blot.

Studies (1)

Purpose

This study investigated effects associated with specimen acquisition method (surgical versus CNB), specimen heterogeneity, analysis method (automated versus manual visualization), and targeted therapies using antibodies against HER2 on the pattern and ratio of full length to total HER2 by IHC. IHC results were verified using Western blot analysis. Staining patterns and intensity of eight breast cancer core biopsy and matched surgical resection specimens were compared. A total of 138 specimens procured by core needle biopsy (8–10 mm long) or surgical resection were obtained before or after neoadjuvant therapy using HER2 antibodies. Specimens were used to compare manual versus automated analysis, to determine the required number of cells or fields of view (FOVs), and to assess potential assay interference due to neoadjuvant therapy. Twelve FFPE invasive breast carcinoma specimens with paired fresh frozen specimens obtained from a commercial biobank were used to compare HER-2 detection by IHC and Western analysis. To determine the ratio of truncated to total HER2, two antibodies were used for dual-color IHC, one that targets the ECD and is indicative of full-length HER2 and another that targets the ICD and is indicative of total HER2, which includes ECD truncated forms common in breast cancer. High intermediate and low ECD/ICD ratios were determined based on activated cell images, but cut-off values were not specified.

Summary of Findings

IHC staining of FFPE specimens revealed heterogeneity of HER2 expression, as differences were observed in the ratio of full-length HER2 (ECD) to total HER2 (ICD), lower expression in single cells within a solid tumor area, and subtle differences in staining between the tumor center and periphery. As expected, the percentage of a specimen that expressed a threshold full-length-to-total HER2 ratio differed among cases. CNB specimens displayed similar staining colors and patterns to matched surgical resection specimens, but staining was more intense and consistent in CNB specimens. The authors attribute these differences to decreased ischemia time and faster fixation of CNB specimens compared to their surgically resected counterparts. Results of automated and manual assessment of HER2 IHC staining agreed for only 91 of the 138 cases evaluated (66%). The majority of discordance occurred in the characterization of the intermediate or a loss of ECD groups (low ratio of ECD/ICD), with more specimens assigned as having a loss of the ECD by manual visualization than automated (37 versus 28 cases, respectively). Although expression was variable, the coefficient of variation between images was minimized by analysis of at least 250 viable and intact cells or 3-8 fields of view at 20X magnification. As expected, comparison of HER2 IHC and western blot data showed that the increase in truncated HER2 (95 kDa) was strongly correlated with a decrease in full length to total (ECD/ICD) HER2 ratio (r=0.72), but IHC analysis showed variability within the specimen that was non detectable by Western blot. Finally, targeted therapies using antibodies against the ECD of HER2 did not significantly affect the ECD/ICD ratio.

  • Biospecimens

    TissueBreast
  • Preservation Types

    FormalinFrozen
  • Diagnoses

    NeoplasticCarcinoma
  • Platforms

    ProteinImmunohistochemistry
    ProteinWestern blot
  • Pre-analytical Factors

    ClassificationPre-Analytical FactorValue(s)
    Biospecimen AcquisitionMethod of tissue acquisition
    Core needle biopsy
    Surgical resection
    Biospecimen Aliquots and ComponentsBiospecimen heterogeneity
    Biospecimen core
    Biospecimen periphery
    Entire tumor examined
    Intratumoral sampling (exact positions not specified)
    Immunohistochemistry SpecificData handling
    Automated visualization
    Manual visualization
    Immunohistochemistry SpecificTargeted peptide/protein
    HER2 ECD
    HER2 ICD
    Immunohistochemistry SpecificTechnology platform
    Western blot
    Western blot SpecificTargeted peptide/protein
    HER-2